SCHEMBL1175752

SCHEMBL1175752

CCN(C)Cc1cc(C)cc(C(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TPMT P51580 1/20 0.52
HCAR1 Q9BXC0 1/20 0.46
ALDH1A1 P00352 3/20 0.41
MRGPRX4 Q96LA9 2/20 0.40
GLA P06280 1/20 0.40
HDAC1 Q13547 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
SLC7A5 Q01650 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
HPGD P15428 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CNR2 P34972 1/20 0.35
ALDH2 P05091 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3351286 0.86 TPMT (0.44) TPMTHCAR1ALDH1A1MRGPRX4GLA
SCHEMBL6646047 0.84 TPMT (0.46) TPMTHCAR1ALDH1A1MRGPRX4MEN1
SCHEMBL12326928 0.84 TPMT (0.57) TPMTHCAR1ALDH1A1MRGPRX4GLA
SCHEMBL3348012 0.84 TPMT (0.48) TPMTHCAR1ALDH1A1MRGPRX4HCAR2
SCHEMBL3352072 0.83 TPMT (0.44) TPMTHCAR1MEN1KMT2A
SCHEMBL1175842 0.83 KDM4E (0.39) ALDH1A1HDAC1SLC7A5TDP1MEN1
SCHEMBL3349426 0.83 TPMT (0.47) TPMTHCAR1ALDH1A1MRGPRX4HCAR2
SCHEMBL3351726 0.80 TPMT (0.44) TPMTHCAR1ALDH1A1MRGPRX4SLC7A5
SCHEMBL6647609 0.80 TPMT (0.44) TPMTHCAR1ALDH1A1MRGPRX4SLC7A5
SCHEMBL13501601 0.78 TPMT (0.64) TPMTHCAR1ALDH1A1MRGPRX4HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410151-B2 Aminomethyl benzene derivatives ACTELION PHARMACEUTICALS LTD (CH) 2013-04-02 US disclosed
EP-2262782-B1 NOVEL AMINOMETHYL BENZENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2012-07-04 EP disclosed
US-20110028449-A1 NOVEL AMINOMETHYL BENZENE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2011-02-03 US disclosed
EP-2262782-A1 NOVEL AMINOMETHYL BENZENE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-12-22 EP disclosed
WO-2009109904-A1 NOVEL AMINOMETHYL BENZENE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028449-A1 NOVEL AMINOMETHYL BENZENE DERIVATIVES CD47, BRD4, BRD3 TPMT 58/4885HCAR1 976/4885ALDH1A1 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.